Gamida Cell Financials

Gamida Cell Stock Summary

Gamida Cell competes with BioLineRx, Ardelyx, Lexicon Pharmaceuticals, Seres Therapeutics, and Immunitybio. Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company was founded in 1998 and is headquartered in Jerusalem, Israel. Gamida Cell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 166 people.

Gamida Cell Key Financial Ratios

Gamida Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Gamida Cell's current stock value. Our valuation model uses many indicators to compare Gamida Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gamida Cell competition to find correlations between indicators driving Gamida Cell's intrinsic value. More Info.Gamida Cell is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gamida Cell's earnings, one of the primary drivers of an investment's value.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.